Q-omics provides the consensus-scored MIR378A profile across patient tissues and cancer cell-line models. MIR378A expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MIR378A is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MIR378A RNA expression shows 14,545 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, COAD, and UVM as cancer lineages where MIR378A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR378A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR378A survival associations across molecular data types. MIR378A RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR378A RNA expression–survival associations across cancer types. High MIR378A expression shows unfavorable associations in PAAD, COAD, UCS and UVM, but favorable associations in HNSC and BLCA. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MIR378A RNA expression.
This table summarizes MIR378A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR378A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR378A shows lower tumor expression in COAD, BRCA, BLCA, CHOL and READ and higher tumor expression in PAAD. The COAD box plot shows higher MIR378A RNA expression in normal versus tumor tissue (log2 FC = −1.010, t-test p < 0.001).
This table shows molecular features associated with MIR378A in patient tissues and cancer cell lines. In patient samples, MIR378A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
